RA0237

antibody from Oursmab

Targeting: F11 FXI

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0237

Provider

Oursmab

Product name

Abelacimab (Biosimilar Reference Antibody) (F11)

Antibody type

Monoclonal

Description

Abelacimab is a novel, first-in-class, fully human monoclonal antibody designed to inhibit factor XI (FXI) and activated factor XI (FXIa). Unlike conventional anticoagulants that target factor Xa or thrombin, Abelacimab aims to separate hemostasis from pathological thrombosis by selectively targeting the intrinsic coagulation pathway. By blocking FXI/FXIa, Abelacimab prevents the amplification of the coagulation cascade without significantly impairing primary hemostasis (platelet function). It is administered intravenously or subcutaneously and is currently under investigation for the prevention and treatment of various thrombotic disorders, including atrial fibrillation, venous thromboembolism (VTE), and in patients undergoing total knee or hip replacement.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.